021-51111890
购物车（）
sales@molnova.cn
Biotin-PEG6-azide
CAS No. 1085938-09-5
Biotin-PEG6-azide ( Biotin-PEG6-N3 )
产品货号. M26909 CAS No. 1085938-09-5
Biotin-PEG6-azide 是一种生物素标记的、基于 PEG 的 PROTAC 连接体，可用于 PROTAC 的合成。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥123 | 有现货 |
|
| 10MG | ￥169 | 有现货 |
|
| 25MG | ￥267 | 有现货 |
|
| 50MG | ￥401 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Biotin-PEG6-azide
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Biotin-PEG6-azide 是一种生物素标记的、基于 PEG 的 PROTAC 连接体，可用于 PROTAC 的合成。
-
产品描述Biotin-PEG6-azide is a biotin-labeled, PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
体外实验PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
体内实验——
-
同义词Biotin-PEG6-N3
-
通路Others
-
靶点Other Targets
-
受体Bacterial
-
研究领域——
-
适应症——
化学信息
-
CAS Number1085938-09-5
-
分子量576.71
-
分子式C24H44N6O8S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (173.40 mM)
-
SMILES[H][C@]12CS[C@@H](CCCCC(=O)NCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])[C@@]1([H])NC(=O)N2
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Makoto Urai,et al. Potent Drugs That Attenuate anti-Candida Albicans Activity of Fluconazole and Their Possible Mechanisms of Action. J Infect Chemother. 2014 Oct;20(10):612-5.
产品手册
关联产品
-
[Tyr8]-Atrial Natriu...
[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
-
3-Chloro-L-Tyrosine
3-氯酪氨酸是髓过氧化物酶催化氧化的特异性标志物，在从人动脉粥样硬化内膜中分离的低密度脂蛋白中显着升高。特别是，髓过氧化物酶卤化血浆蛋白中的酪氨酸残基并产生3-氯酪氨酸(CY)。
-
Taraxeryl acetate
Taraxeryl acetate shows the significant antiviral activity against herpes simplex virus (type II). It has less effect on cell cycle arrest and apoptosis of AGS cells than taraxerol.
